BMJ, doi: 10.1136/bmj.39314.620174.80, (Published 30 August 2007)

Research

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

¹ Institute of Health Economics, Edmonton, AB, Canada, T5J 3N4, ² Division of Internal Medicine, Department of Medicine, Faculty of Medicine and Dentistry, 2F1 WMC, University of Alberta Hospital, Edmonton, AB, Canada, T6G 2B7, ³ College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada, S7N 5C9, ⁴ Division of Cardiology, Department of Medicine, Faculty of Medicine and Dentistry, 2F1 WMC, University of Alberta Hospital, Edmonton, AB, Canada, T6G 2B7, ⁵ Department of Public Health Sciences, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, T6G 2G3

Objective To review the literature on the association between antidiabetic agents and morbidity and mortality in people with heart failure and diabetes.

Design Systematic review and meta-analysis of controlled studies (randomised trials or cohort studies) evaluating antidiabetic agents and outcomes (death and admission to hospital) in patients with heart failure and diabetes.

Data sources Electronic databases, manual reference search, and contact with investigators.

Review methods Two reviewers independently extracted data. Risk estimates for specific treatments were abstracted and pooled estimates derived by meta-analysis where appropriate.

Results Eight studies were included. Three of four studies found that insulin use was associated with increased risk for all cause mortality (odds ratio 1.25, 95% confidence interval 1.03 to 1.51; 3.42, 1.40 to 8.37 in studies that did not adjust for diet and antidiabetic drugs; hazard ratio 1.66, 1.20 to 2.31; 0.96, 0.88 to 1.05 in the studies that did). Metformin was associated with significantly reduced all cause mortality in two studies (hazard ratio 0.86, 0.78 to 0.97) compared with other antidiabetic drugs and insulin; 0.70, 0.54 to 0.91 compared with sulfonylureas); a similar trend was seen in a third. Metformin was not associated with increased hospital admission for any cause or for heart failure specifically. In four studies, use of thiazolidinediones was associated with reduced all cause mortality (pooled odds ratio 0.83, 0.71 to 0.97, I²=52%, P=0.02). Thiazolidinediones were associated with increased risk of hospital admission for heart failure (pooled odds ratio 1.13 (1.04 to 1.22), I²=0%, P=0.004). The two studies of sulfonylureas had conflicting results, probably because of differences in comparator treatments. Important limitations were noted in all studies.

Conclusion Metformin was the only antidiabetic agent not associated with harm in patients with heart failure and diabetes. It was associated with reduced all cause mortality in two of the three studies.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Focus on diabetes

Fiona Godlee
BMJ 2007 335: 0. [Extract] [Full Text]

Self management of type 2 diabetes

Frank J Snoek
BMJ 2007 335: 458-459. [Extract] [Full Text] [PDF]

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Irene M Stratton, Amanda I Adler, H Andrew W Neil, David R Matthews, Susan E Manley, Carole A Cull, David Hadden, Robert C Turner, and Rury R Holman
BMJ 2000 321: 405-412. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Opie, L. H., Knuuti, J. (2009). The adrenergic-Fatty Acid load in heart failure.. J Am Coll Cardiol 54: 1637-1646 [Abstract] [Full text]  
• Raj, S. R., Stein, C. M., Saavedra, P. J., Roden, D. M. (2009). Cardiovascular Effects of Noncardiovascular Drugs. Circulation 120: 1123-1132 [Full text]  
• Sasaki, H., Asanuma, H., Fujita, M., Takahama, H., Wakeno, M., Ito, S., Ogai, A., Asakura, M., Kim, J., Minamino, T., Takashima, S., Sanada, S., Sugimachi, M., Komamura, K., Mochizuki, N., Kitakaze, M. (2009). Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-Activated Protein Kinase. Circulation 119: 2568-2577 [Abstract] [Full text]  
• Cheng, J. W. M., Bhatt, S. H., Goldman-Levine, J. D. (2009). The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease. Journal of Pharmacy Practice 22: 179-193 [Abstract]  
• Gundewar, S., Calvert, J. W., Jha, S., Toedt-Pingel, I., Yong Ji, S., Nunez, D., Ramachandran, A., Anaya-Cisneros, M., Tian, R., Lefer, D. J. (2009). Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure. Circ. Res. 104: 403-411 [Abstract] [Full text]  
• Swift, T. M. M. (2009). Metformin Use in Patients With Diabetes and Heart Failure: Cause for Concern?. Diabetes Spectr. 22: 18-20 [Full text]  
• Nathan, D. M. (2008). Glycemic Management of Type 2 Diabetes: How Tight Is Right and How to Get There. Arch Intern Med 168: 2064-2066 [Full text]  
• McAlister, F. A., Eurich, D. T., Majumdar, S. R., Johnson, J. A. (2008). The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 10: 703-708 [Abstract] [Full text]  
• Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochelliere, R., Staniloae, C. S., Mavromatis, K., Saw, J., Hu, B., Lincoff, A. M., Tuzcu, E. M., for the PERISCOPE Investigators, (2008). Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial. JAMA 299: 1561-1573 [Abstract] [Full text]  
• Marinovic, J., Ljubkovic, M., Stadnicka, A., Bosnjak, Z. J., Bienengraeber, M. (2008). Role of sarcolemmal ATP-sensitive potassium channel in oxidative stress-induced apoptosis: mitochondrial connection. Am. J. Physiol. Heart Circ. Physiol. 294: H1317-H1325 [Abstract] [Full text]  
• (2007). Which Antidiabetic Drugs Are Safest for People with Diabetes and Heart Failure?. JWatch General 2007: 3-3 [Full text]  
• Snoek, F. J (2007). Self management of type 2 diabetes. BMJ 335: 458-459 [Full text]  

Rapid Responses:

Read all Rapid Responses

Insulin treatment seems not rational

Philipp Conradi
bmj.com, 20 Oct 2007 [Full text]

Renal Failure in Heart Failure

Mahmood Ahmad, et al.
bmj.com, 31 Oct 2007 [Full text]

Metformin is safe also in older diabetic patients with heart failure

Andrea Corsonello, et al.
bmj.com, 1 Feb 2008 [Full text]

Online poll

Find out more >>